PMS-LOPERAMIDE HYDROCHLORIDE SOLUTION.2MG/ML

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

LOPERAMIDE HYDROCHLORIDE

থেকে পাওয়া:

PHARMASCIENCE INC

এটিসি কোড:

A07DA03

INN (আন্তর্জাতিক নাম):

LOPERAMIDE

ডোজ:

0.2MG

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

LOPERAMIDE HYDROCHLORIDE 0.2MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

230ML

প্রেসক্রিপশন টাইপ:

OTC

থেরাপিউটিক এলাকা:

ANTIDIARRHEA AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0111332002; AHFS:

অনুমোদন অবস্থা:

MARKETED

অনুমোদন তারিখ:

1993-12-31

পণ্য বৈশিষ্ট্য

_pms-LOPERAMIDE & pms-LOPERAMIDE HYDROCHLORIDE SOLUTION Product
Monograph _
_Page 1 of 38 _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PMS-LOPERAMIDE
Loperamide Hydrochloride Tablets
Caplet, 2 mg, oral
USP
and
PMS-LOPERAMIDE HYDROCHLORIDE SOLUTION
Loperamide Hydrochloride Oral Solution
Solution, 0.2 mg / mL, Oral
USP
Antidiarrheal agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
www.pharmascience.com
Date of Initial Authorization:
pms-LOPERAMIDE HYDROCHLORIDE SOLUTION:
June 2, 1993
pms-LOPERAMIDE
August 2, 1996
Date of Revision:
June 26, 2023
Submission Control Number: 272133
_pms-LOPERAMIDE & pms-LOPERAMIDE HYDROCHLORIDE SOLUTION Product
Monograph _
_Page 2 of 38 _
_ _
RECENT MAJOR LABEL CHANGES
5 OVERDOSAGE, Addition of drug withdrawal syndrome
06/2022
7 WARNINGS AND PRECAUTIONS, Addition of drug withdrawal syndrome
06/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.......................................................................................................
2
TABLE OF CONTENTS
.........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................................
4
1
INDICATIONS
........................................................................................................................
4
1.1
Pediatrics
...........................................................................................................................
4
1.2
Geriatrics
............................................................................................................................
4
2
CONTRAINDICATIONS
...........................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.....................................................................